Medical therapy in Crohn's disease

References

• Peppercorn MA. Advances in drug therapy for inflammatory bowel disease. Ann Intern Med 1990: 112(1): 50–60
   PubMed Web of Science ®Google Scholar
• Podolsky DK. Inflammatory bowel disease. 2. N Engl J Med 1991: 325(14): 1008–16
   PubMed Web of Science ®Google Scholar
• Goldman P, Peppercorn MA. Drug therapy: sulfasalazine. N Engl J Med 1975: 293(1): 20–3
   PubMed Web of Science ®Google Scholar
• Nielsen OH, Bukhave K, Elmgreen J, et al. Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid. Dig Dis Sci 1987: 32(6): 577–82
   PubMed Web of Science ®Google Scholar
• Miyachi Y, Yoshioka A, Imamura S, et al. Effect of sulphasalazine and its metabolites on the generation of reactive oxygen species. Gut 1987: 28(2): 190–5
   PubMed Web of Science ®Google Scholar
• Taffet SL, Das KM. Sulfasalazine: adverse effects and desensitization. Dig Dis Sci 1983: 28(9): 833–42
   PubMed Web of Science ®Google Scholar
• Sutherland LR, Martin F, Greer S, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987: 92(6): 1894–8
   PubMed Web of Science ®Google Scholar
• Christensen LA, Failingborg J, Abildgaard K, et al. Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man. Aliment Pharmacol Ther 1990: 4(5): 523–33
   PubMed Web of Science ®Google Scholar
• Meyers S, Sactar DB, Present DH. et al. Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine: a prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial. Gastroenterology 1987: 93(6): 1255–62
   PubMed Web of Science ®Google Scholar
• Peppercorn MA. General principles of medical treatment of ulcerative colitis and Crohn's disease. Semin Gastrointest Dis 1991: 2(2): 76–89
   Google Scholar
• Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979: 77(4 Pt 2): 847–69
   PubMed Web of Science ®Google Scholar
• Van Hees PA, Van Lier HJ, Van Elteren PH, et al. Effect of sulphasalazine in patients with active Crohn's disease: a controlled double-blind study. Gut 1981: 22(5): 404–9
   PubMed Web of Science ®Google Scholar
• Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984: 86(2): 249–66
   PubMed Web of Science ®Google Scholar
• Rasmussen SN, Bondesen S, Hvidberg EF, et al. 5-Aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans. Gastroenterology 1982: 83(5): 1062–70
   PubMed Web of Science ®Google Scholar
• Mahida YR, Jewell DP. Slow-release 5-amino-salicylic acid (Pentasa) for the treatment of active Crohn's disease. Digestion 1990: 45(2): 88–92
   PubMed Web of Science ®Google Scholar
• Singleton J, Gitnick G, Hanauer S, et al. Response of Crohn's disease to oral pentasa (controlled-release mesalamine) as a fonction of disease location and prior therapy: results of a multicenter study. (Abstr) Gastroenterology 1991: 100(5 Pt 2): A251
   Google Scholar
• Williams CN. Role of rectal formulations: suppositories. Scand J Gastroenterol 1990: 25(Suppl 172): 60–2
   Web of Science ®Google Scholar
• Rijk MC, van Hogezand RA, van Lier HJ, et al. Sulphasalazine and prednisone compared with sulphasalazine for treating active Crohn disease: a double-blind, randomized, multicenter trial. Ann Intern Med 1991: 114(6): 445–50
   PubMed Web of Science ®Google Scholar
• Olaison G, Sjodahl R, Tagesson C. Glucocorticoid treatment in ileal Crohn's disease: relief of symptoms but not of endoscopically viewed inflammation. Gut 1990: 31(3): 325–8
   PubMed Web of Science ®Google Scholar
• Modigliani R, Mary JY, Simon JF, et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease: evolution on prednisolone. Gastroenterology 1990: 98(4): 811–8
   PubMed Web of Science ®Google Scholar
• Campieri M, Brignola C, Miglioli M, et al. Medical management of inflammatory bowel disease. Curr Opin Gastroenterol 1991: 7: 607–16
   Web of Science ®Google Scholar
• Wolman SL, Greenberg GR. Oral budesonide in active Crohn's disease: an initial experience. (Abstr) Gastroenterology 1991: 100(5 Pt 2): A263
   PubMedGoogle Scholar
• Löfberg R, Danielsson Å, Salde L. Oral budesonide in active ileocecal Crohn's disease: a pilot trial with a topically acting steroid. (Abstr) Gastroenterology 1991: 100(5 Pt 2): A226
   Google Scholar
• Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn's disease with 6-mercaptopurine: a long-term, randomized, double-blind study. N Engl J Med 1980: 302(18): 981–7
   PubMed Web of Science ®Google Scholar
• O'Brien JJ, Bayless TM, Bayless JA. Use of azathioprine or 6-mercaptopurine in the treatment of Crohn's disease. Gastroenterology 1991: 101(1): 39–46
   PubMed Web of Science ®Google Scholar
• Present DH, Meltzer SJ, Krumholz MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short-and long- term toxicity. Ann Intern Med 1989: 111(8): 641–9
   PubMed Web of Science ®Google Scholar
• Alstead EM, Ritchie JK, Lennard-Jona JE, et al. Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology 1990: 99(2): 443–6
   PubMed Web of Science ®Google Scholar
• Markowitz J, Rosa J, Grancher K, et al. Long-term 6-mercaptopurine treatment in adolescents with Crohn's disease. Gastroenterology 1990: 99(5): 1347–51
   PubMed Web of Science ®Google Scholar
• Freeman HJ. Immunosuppressive drug therapy of inflammatory bowel disease. Endosc Rev 1991: 8(8): 26–8
   Google Scholar
• Brynskov J, Freund L, Rasmussen SN, et al. A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease. N Engl J Med 1989: 321(13): 845–50
   PubMed Web of Science ®Google Scholar
• Drewe J, Beglinger C, Kissel T. The functional length of the small bowel determines the extent of peroral cyclosporine absorption in man. (Abstr) Gastroenterology 1991: 100 (5 Pt 2): A684
   Google Scholar
• Kozarek RA, Patterson DJ, Gelfand MD, et al. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989: 110(5): 353–6
   PubMed Web of Science ®Google Scholar
• Baron TH, Truss CD, Elson CO. Steroid sparing effect of oral methotrexate in refractory inflammatory bowel disease (IBD). (Abstr) Gastroenterology 1991: 100(5 Pt 2): A195
   Google Scholar
• Mayer L, Sachar DB. Efficacy of chloroquine in the treatment of inflammatory bowel disease. (Abstr) Gastroenterology 1988: 94: A293
   Web of Science ®Google Scholar
• Ursing B, Aim T, Barany F, et al. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II. Result. Gastroenterology 1982: 83(3): 550–62
   PubMed Web of Science ®Google Scholar
• Brandt LJ, Bernstein LH, Boley SJ, et al. Metronidazole therapy for perineal Crohn's disease: a follow-up study. Gastroenterology 1982: 83(2): 383–7
   PubMed Web of Science ®Google Scholar
• Brignola C, Campieri M, Farruggia P, et al. The possible utility of steroids in the prevention of relapses of Crohn's disease in remission: a preliminary study. J Clin Gastroenterol 1988: 10(6): 631–4
   PubMed Web of Science ®Google Scholar
• Thomson AB, Sutherland LR. Maintenance of remission in patients with Crohn's disease. Endosc Rev 1991: 8(8): 10–26
   Google Scholar
• International Mesalazine Study Group. Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn's disease. Aliment Pharmacol Ther 1990: 4(1): 55–64
   PubMed Web of Science ®Google Scholar
• Brignola C, Iannone P, Pasquali S, et al. Placebo—controlled trial of oral 5-ASA in relapse prevention of Crohn's disease. Dig Dis Sci 1992: 37(1): 29–32
   PubMed Web of Science ®Google Scholar
• Salomon P, Kornbluth A, Aisenberg J, et al. How effective are current drugs for Crohn's disease? A meta-analysis. (Abstr) Gastroenterology 1991: 100(5 Pt 2): A247
   Google Scholar
• Hodgson HJ, Mazlam MZ. Review article: assessment of drug therapy in inflammatory bowel disease. Aliment Pharmacol Ther 1991: 5(6): 555–84
   PubMed Web of Science ®Google Scholar